EcoDrugPlus

Coagulation Factor Ii (Thrombin) Receptor

Ensembl ID : ENSAOCG00000005299
Gene Symbol: F2R
1 Cross references
211 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSAOCG00000015124
Gene Symbol: F3
3 Cross references
199 Possible Orthologues:

Coagulation Factor Vii-Like

Ensembl ID : ENSAOCG00000006543
Gene Symbol: LOC111566046
3 Cross references
203 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSAOCG00000023979
Gene Symbol: F10
1 Cross references
240 Possible Orthologues:

Coagulation Factor X-Like

Ensembl ID : ENSAOCG00000006507
Gene Symbol: LOC111566049
3 Cross references
241 Possible Orthologues:

Coagulation Factor Xi-Like

Ensembl ID : ENSAOCG00000019236
Gene Symbol: LOC111572227
2 Cross references
203 Possible Orthologues:

Coiled-Coil Domain Containing 6

Ensembl ID : ENSAOCG00000014000
Gene Symbol: CCDC6
3 Cross references
208 Possible Orthologues:

Collagenase 3-Like

Ensembl ID : ENSAOCG00000010276
Gene Symbol: LOC111583609
2 Cross references
173 Possible Orthologues:

Collagenase 3-Like

Ensembl ID : ENSAOCG00000010267
Gene Symbol: LOC111583610
2 Cross references
306 Possible Orthologues:

Colony Stimulating Factor 1 Receptor

Ensembl ID : ENSAOCG00000007456
Gene Symbol: CSF1R
3 Cross references
207 Possible Orthologues:

Complement C5

Ensembl ID : ENSAOCG00000012681
Gene Symbol: C5
2 Cross references
216 Possible Orthologues:

Corticotropin Releasing Hormone Receptor 1

Ensembl ID : ENSAOCG00000012618
Gene Symbol: CRHR1
3 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).